Acceptable reflexive panel for the differential diagnosis of acquired neuromuscular junction disorders. Panel includes acetylcholine receptor binding, blocking, and modulating antibodies; P/Q-type voltage-gated calcium and potassium channels; titin antibody; striated muscle antibodies; and leucine-rich glioma-inactivated protein 1 antibody and contactin-associated protein-2 antibody IgG with reflex to titers.
Quantitative Radioimmunoassay/Qualitative Radiobinding Assay/Semi-Quantitative Flow Cytometry/Semi-Quantitative Indirect Fluorescent Antibody
Refer to individual components
Serum separator tube (SST).
Separate serum from cells ASAP or within 2 hours of collection. Transport 2 mL serum. (Min: 1 mL)
Plasma. Contaminated, hemolyzed, or severely lipemic specimens.
Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year
Effective August 15, 2016
|0080009||Acetylcholine Receptor Binding Antibody||
|0099580||Acetylcholine Receptor Blocking Antibody||Effective November 18, 2013
|0099521||Acetylcholine Receptor Modulating Antibody||Effective August 20, 2012
|0092628||P/Q-Type Voltage-Gated Calcium Channel (VGCC) Antibody||Effective November 14, 2011
|2004890||Voltage-Gated Potassium Channel (VGKC) Antibody, Serum||
|2005636||Titin Antibody||Effective January 17, 2012
|0050746||Striated Muscle Antibodies, IgG with Reflex to Titer||Less than 1:40|
|2009460||Leucine-Rich, Glioma-Inactivated Protein 1 Antibody, IgG and Contactin-Associated Protein-2 Antibody, IgG with Reflex to Titers, Serum||
Refer to report.
Compliance Statement A: For laboratory developed tests using a manufacturer labeled ASR as the reagent providing the specificity of the assay. Analyte Specific Reagent. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, the FDA has determined that such clearance or approval is not necessary.
If Acetylcholine Receptor Binding Antibody result is greater than 0.4 nmol/L or Acetylcholine Receptor Blocking Antibody result is greater than 26 percent, then Acetylcholine Receptor Modulating Antibody will be added. If Striated Muscle Ab is detected, then a titer will be added. If VGKC is Indeterminate or Positive, LGI1 Antibody IgG and CASPR2 Antibody IgG will be added. If LGI1 antibody IgG is positive, then LGI1 antibody IgG titer will be added. If CASPR2 antibody IgG is positive, then CASPR2 antibody IgG titer will be added. Additional charges apply.
83519 x3; 83516 x2; 86255; if reflexed, add 83516 and/or 86256 and/or 86255x2, if further reflex add 86256 per titer
|Component Test Code*||Component Chart Name||LOINC|
|0050747||Striated Muscle Antibodies, IgG Screen||49692-7|
|0080009||Acetylcholine Binding Antibody||11034-6|
|0092629||P/Q-Type Calcium Channel Antibody||33980-4|
|0099580||Acetylcholine Blocking Antibody||42937-3|
|2004890||Voltage-Gated Potassium Channel Ab, Ser||41871-5|
- AChR Binding Antibody
- AChR Antibody
- Anti-Skeletal Muscle IgG Antibodies
- Anti-Striated Antibody
- anti-tintin Ab
- Muscle (Skeletal) Antibodies
- Muscle nicotinic Acetylcholine Receptor
- Myasthenia Gravis Antibodies
- Myoid Antibody
- Skeletal Muscle Antibodies
- Striational Antibodies
- VGCC Ab
- VGKC Ab
- Voltage-Gated Calcium Channel Antibody
- Voltage-Gated Potassium Channel Antibody